Clareo Health | A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and non-pregnant women aged ≥18 years
Hemoglobin A1c (HbA1c) ≥7.5% and ≤10.5%
Type 2 diabetes on insulin or insulin + oral antihyperglycemic medication
Participants with presumed diabetic kidney disease with or without hypertensive nephrosclerosis diagnosed with moderate or severe CKD with estimated glomerular filtration rate (eGFR) of ≥15 to \<60 milliliters per minute (mL/min)/1.73 meter squared (m\^2)
Able and willing to perform multiple daily injections
Body mass index (BMI) between 23 and 45 kilogram/square meter (kg/m\^2)
You may not be if
Stage 5 CKD as defined by eGFR \<15 mL/min/1.73 m\^2 OR having required dialysis
Rapidly progressing renal dysfunction likely to require renal replacement
History of a transplanted organ
Type 1 diabetes mellitus
At screening a systolic blood pressure of ≥150 mmHg or a diastolic blood pressure of ≥90 mmHg with or without antihypertensive medication
An episode of ketoacidosis or hyperosmolar state/coma in the past 6 months or a history of severe hypoglycemia in the past 3 months prior to the Screening Visit
Cardiovascular conditions within 12 weeks prior to randomization: acute myocardial infarction, New York Heart Association (NYHA) class III or class IV heart failure, or cerebrovascular accident (stroke)
Acute or chronic hepatitis
Signs and symptoms of chronic or acute pancreatitis, or were in the past diagnosed with pancreatitis
Serum calcitonin ≥35 picograms per milliliter (pg/mL) at Screening Visit
Self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma
Known history of untreated proliferative retinopathy
